Skip to content

Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease

Stem Cell Revascularization in Patients With Critical Limb Ischemia

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00913900
Acronym
SCRIPT-CLI
Enrollment
10
Registered
2009-06-04
Start date
2009-05-31
Completion date
2013-12-31
Last updated
2014-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Occlusive Disease, Critical Limb Ischemia, Vascular Diseases

Keywords

Arterial Occlusive Diseases, Vascular Disease

Brief summary

Peripheral artery disease (PAD) due to leg artery blockages can result in painful leg muscles, skin ulcers and infection due to poor blood flow. In severe forms, the only treatment may be amputation. Adult stem cells injected into affected legs may cause new blood vessel formation and improve blood flow. The purpose of this study is to determine the feasibility and safety of injecting adult stem cells into the leg muscles of patients with severe PAD, in an attempt to improve blood flow.

Detailed description

Lower extremity peripheral artery disease (PAD) is a common, debilitating and potentially life-threatening illness. Obstructive PAD can progress to limb-threatening ischemia with rest pain, ulcers, and gangrene requiring amputation unless blood flow to the ischemic limb can be restored. Surgical revascularization options are often limited by arteries that are too small to bypass. Patient co-morbidities also make surgical options risky. Percutaneous revascularization techniques are similarly limited by small distal artery caliber, technical difficulty and high restenosis rates. Amputation may be the only treatment option for non-healing ulcers or gangrene. Direct intramuscular injection of adult stem cells may result in improved lower extremity perfusion, symptomatic improvement and limb salvage in patients with critical limb ischemia not optimal for conventional revascularization. This study aims to demonstrate the safety and feasibility of this therapeutic approach.

Interventions

BIOLOGICALautologous CD133+ cells

Intramuscular injection

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Ambulatory critical limb ischemia (Rutherford Score 4/5) * Not optimal for surgical or catheter-based revascularization * Obstructive atherosclerosis of at least 1 major artery in both limbs * Ankle-Brachial Index \<0.6 or Absolute Ankle pressure \<60mmHg or toe pressure \<40mmHg or pulse volume recording that is flat or barely pulsatile

Exclusion criteria

* Gangrene(Rutherford 6) or pre-existing major tissue loss * Unstable Angina, MI, stroke, CHF (class III or IV) within 6 months of study treatment

Design outcomes

Primary

MeasureTime frame
Death or amputation6 months

Secondary

MeasureTime frame
Vascular hemodynamics and function6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026